This is a real-world medical entrance exam question, please give the true answer based on the question and selection. Topic name: JIPMER 2017, Subject name: Pharmacology
[{'content': 'Newer monoclonal antibody approved for rheumatoid ahritis is: \nSelect and explain. \nA. Durvalumab, B. Pembrolizumab, C. Nivolumab, D. Sarilumab', 'role': 'user'}, {'content': 'Answer: D \nExplanation: Sarilumab: Monoclonal antibody against IL6, used for rheumatoid ahritis. Six - SARILUMAB - monoclonal antibody | Interleukin Durvalumab: Monoclonal antibody for urothelial carcinoma. DURVALUMAB - Urothelial Ca Nivolumab/Sarilumab: Monoclonal antibody for non small cell lung cancer(NSCLC). Durvalumab, Nivolumab, Sarilumab: Target program death ligand of T cell. T cell get activated and kills cancer cells.', 'role': 'assistant'}]